Indirect funds are essential for supporting the research infrastructure needed to develop innovative solutions to the most pressing health challenges.

National Institutes of Health slashed overhead costs allowed under its grants to match private foundations, but the two don't ...

Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.

Private investment in pharmaceutical research can't replace the NIH. Both public investment and the private sector are needed ...

In statements and interviews with The Crimson, nine life sciences researchers at Harvard — from the Harvard School of Public ...

Of course the effects will vary across research institutions, as institutions differ markedly in their operating models and ...

Two key staff members at the National Institutes of Health (NIH) are reportedly leaving the agency amid ongoing efforts by ...

The memo, penned by NIH Deputy Director for Extramural Research Michael Lauer and NIH Chief Grants Officer Michelle Bulls, ...

Here’s a look at what the Trump administration’s decision to cut overhead funding for biomedical research means for ...

Efforts by the Trump administration to drastically cut federal investments in medical research are threatening to kneecap ...

The White House budget office has ordered a sweeping pause on all federal grants, loans and financial assistance not directly provided to individuals.